Skip to content Skip to footer
Subscribe Now
NEWS

Boehringer Ingelheim Inks $500M+ Deal with Sitryx Therapeutics for Novel Oral Immune Disease Therapies

Shots: Sitryx Therapeutics has granted BI an exclusive license to a preclinical, small molecule program, offering a disease-modifying treatment approach across multiple autoimmune & inflammatory disease indications As per the deal, BI will receive an exclusive global license to the multiple assets & related IP to the small molecule inhibitor program, plus it will assume…
2 days ago

Read more

NEWS

SteinCares Forges Licensing Agreement with Shilpa Biologicals for Biosimilars Across Latin America

Shots: SteinCares has entered into a strategic licensing agreement with Shilpa Medicare to commercialize a biosimilar across Latin America (LATAM) As per the deal, SteinCares secures exclusive rights to register, commercialize, & distribute the biosimilar across the region, while SBPL will finalize development & undertake commercial manufacturing at its Dharwad, India facility Partnership combines SBPL’s…
3 days ago

Read more

NEWS

Frontier Biotechnologies and GSK Forge ~$1B Global Licensing Deal for siRNA Therapeutics

Shots: Frontier has entered into an exclusive licensing agreement with GSK for two Small Interfering RNA (siRNA) assets in immunology, incl. one IND-stage candidate & one preclinical program As per the deal, GSK will gain exclusive global rights to develop, manufacture, & commercialize two of Frontier’s siRNA candidates, while Frontier will receive $40M upfront, up…
4 days ago

Read more

NEWS

Unnatural Products Signs ~$1.8B Licensing Deal with Novartis to Develop Macrocyclic Peptide Therapeutics

Shots: Unnatural Products has entered a research collaboration & licensing agreement with Novartis for an undisclosed cardiovascular program developed using UNP’s AI-enhanced macrocycle platform Under the deal, Novartis will handle IND-enabling studies & subsequent clinical development, manufacturing, & global commercialization of products emerging from the collaboration As per the terms, UNP will receive ~$100M in…
February 19, 2026

Read more

NEWS

Lotus Pharmaceutical Partners with Formycon to Commercialize FYB206 (Biosimilar, Keytruda) across APAC Region

Shots: Formycon & Lotus have reported the conclusion of their exclusive license agreement for Formycon’s FYB206, a biosimilar version of Keytruda (Pembrolizumab), in the APAC market Upon closing, Formycon will receive an upfront payment, plus potential development & regulatory milestone payments, & a share of gross profits after launch, while retaining responsibility for manufacturing &…
February 12, 2026

Read more

NEWS

Madrigal Pharmaceutical Forges ~$4.46B siRNA Deal with Ribo Life Science to Expand Genetically Targeted MASH Pipeline

Shots: Madrigal has entered into an exclusive global license agreement with Suzhou Ribo Life Science & its subsidiary Ribocure Pharmaceuticals for 6 preclinical siRNA programs in metabolic dysfunction-associated steatohepatitis (MASH) The deal allows Madrigal to pair a targeted gene-silencing siRNA approach with Rezdiffra to assess whether genetically reducing disease drivers can enhance its therapeutic impact,…
February 11, 2026

Read more

NEWS

Memo Therapeutics and CSL Partner to Advance Recombinant Polyclonal IgG Technology

Shots: Memo has entered into a strategic collaboration & exclusive option-to-license agreement with CSL for Memo’s recombinant polyclonal IgG technology As per the deal, Memo will use its Dropzylla platform for cloning human antibody repertoires & polyclonal antibody expression to develop recombinant polyclonal IgG products, while CSL will obtain an option to exclusively license those…
February 9, 2026

Read more

NEWS

Eisai and Henlius Partner to Commercialize Serplulimab in Japan

Shots: Eisai & Henlius have entered into an exclusive commercialization & co-exclusive development & manufacturing license agreement for serplulimab (Hetronifly in the EU) in Japan As per the deal, Eisai will obtain exclusive rights to commercialize serplulimab in Japan in exchange for $75M upfront, ~$80.01M in regulatory milestones, ~$233.3M in sales milestones, with double-digit royalties…
February 6, 2026

Read more

Load more